G. Pissart

Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.

A. Thiery-Vuillemin, A. Birtle, G. Ploussard, 2020, European urology.

Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study

A. Thiery-Vuillemin, A. Birtle, G. Ploussard, 2018, ESMO Open.

Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study

W. Hilgers, T. Elliott, M. Hatzinger, 2019, BMC Cancer.

630P Apalutamide for non-metastatic castration resistant prostate cancer (nmCRPC): A comparison of real-life experience from an international named patient program (NPP) vs the prior phase III clinical study

J. McCaffrey, H. Payne, M. Santoni, 2020 .

Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

B. Tombal, C. Sternberg, Robert J. Jones, 2019, JAMA oncology.

Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

B. Tombal, C. Sternberg, Robert J. Jones, 2019, JAMA oncology.

Assessment of the safety of glucocorticoid regimens in combination with abiraterone acetate for metastatic castration-resistant prostate cancer

F. Lefresne, G. Pissart, Florence Nave Shelby, 2019 .